Managing Multiple Medications: When a Geriatrician Can Help

Polypharmacy — the concurrent use of 5 or more medications — affects a substantial portion of the older adult population in the United States and carries measurable risks that compound with age. This page examines how geriatricians evaluate, rationalize, and manage complex medication regimens in older patients, what clinical tools structure that process, and which situations call for specialist-level polypharmacy review. The geriatrics field as a whole has developed specific frameworks for this problem that differ meaningfully from standard primary care approaches.

Definition and scope

Polypharmacy is formally defined in geriatric literature as the use of 5 or more concurrent medications, with "hyperpolypharmacy" applied to regimens of 10 or more drugs. Among adults aged 65 and older, the Centers for Disease Control and Prevention (CDC) has reported that more than 40 percent use 5 or more prescription medications. When over-the-counter drugs, vitamins, and herbal supplements are included, the actual pill burden frequently exceeds reported prescription counts.

The scope of harm is not hypothetical. Adverse drug events (ADEs) account for approximately 1 in 3 hospital admissions among older adults (American Geriatrics Society [AGS], Beers Criteria Update 2023). The Agency for Healthcare Research and Quality (AHRQ) classifies ADEs as one of the most common and preventable types of patient harm in hospital and outpatient settings alike.

Geriatricians approach polypharmacy through the lens of medication review and polypharmacy reduction, which treats each medication as a variable in a dynamic system — not a static prescription. The central challenge is that physiological changes associated with aging alter how drugs are absorbed, distributed, metabolized, and excreted, a framework documented in the regulatory context for geriatrics that shapes prescribing standards nationally.

How it works

A geriatrician-led medication review is a structured clinical process, not a simple list check. The workflow typically follows these discrete phases:

Complete medication reconciliation — Compiling all prescription drugs, over-the-counter medications, vitamins, and supplements from pharmacy records, patient recall, and caregiver input. Discrepancies between what is prescribed and what is actually taken are documented.
Pharmacokinetic and pharmacodynamic assessment — Evaluating how aging bodies process each drug. Renal clearance, hepatic metabolism, altered volume of distribution, and reduced protein binding all shift therapeutic windows in adults over 65. The Cockcroft-Gault equation is the standard tool for estimating creatinine clearance and adjusting renally cleared drug doses.
Screening against explicit criteria — The AGS Beers Criteria, updated in 2023, lists drug classes and specific agents considered potentially inappropriate for older adults. A parallel tool, the STOPP/START criteria (Screening Tool of Older Person's Prescriptions / Screening Tool to Alert to Right Treatment), provides a complementary European-origin framework used in clinical research and quality measurement.
Drug-drug and drug-disease interaction review — Identifying combinations that elevate bleeding risk, increase sedation, prolong QT interval, or destabilize chronic conditions. The FDA's Drug Interaction Database resources support standardized interaction checking.
Deprescribing decisions — Systematically tapering or discontinuing medications whose risks outweigh benefits in the current clinical context. Deprescribing is distinct from stopping — it requires a taper schedule, monitoring plan, and reassessment timeline.
Reassessment and follow-up — Confirming that the rationalized regimen achieves its intended outcomes without substituting new adverse effects for old ones.

Geriatric review vs. standard primary care review: A primary care physician managing a patient with 4 chronic conditions may optimize each condition's pharmacotherapy in isolation. A geriatrician evaluates the regimen as an integrated system, explicitly accounting for frailty status, functional goals, life expectancy, and patient-defined priorities — factors formally addressed in a comprehensive geriatric assessment.

Common scenarios

Geriatrician involvement in medication management becomes most clinically relevant in identifiable situations:

Post-hospitalization medication cascade — A patient discharged after a cardiac event may leave the hospital on 3 to 5 new medications added to an existing regimen, creating a combined burden of 12 or more drugs within 48 hours of discharge.
Falls with unexplained cause — Sedating antihistamines, benzodiazepines, antipsychotics, alpha-blockers, and certain antihypertensives all appear on the Beers Criteria list for fall risk. Identifying and removing or substituting these agents is a core falls and fall prevention intervention.
Cognitive decline or new delirium — Anticholinergic medications (bladder agents, older antihistamines, tricyclic antidepressants) accumulate burden scored by the Anticholinergic Cognitive Burden (ACB) scale. An ACB score of 3 or higher for a single agent, or cumulative scoring across agents, correlates with measurable cognitive impairment in older adults.
Uncontrolled symptoms despite multiple agents — When a patient takes 3 antihypertensives but blood pressure remains uncontrolled, the problem may be a drug interaction, adherence failure, or an agent counteracting another — not a dosing gap.
Patients managing multiple chronic conditions — The intersection of managing multiple chronic conditions with age-related pharmacokinetic change is precisely the domain where geriatric-level review adds the most clinical value.

Decision boundaries

Not every older adult with a complex medication list requires geriatric specialist involvement. Structured decision boundaries help clarify when specialist review shifts from optional to clinically indicated.

Indicators favoring geriatric specialist review:

Regimen of 10 or more concurrent medications where primary care adjustment has not resolved functional decline or adverse events
Presence of frailty (as scored by a validated instrument such as the Clinical Frailty Scale or the Fried Frailty Phenotype) combined with a regimen of 5 or more drugs
ADEs causing hospitalization in the preceding 12 months
Cognitive impairment that complicates medication adherence assessment
Active deprescribing goals in the context of hospice or palliative care for older adults where minimizing pill burden is a quality-of-life priority

Situations where primary care-led review is typically sufficient:

A regimen of 5 to 7 well-tolerated medications with stable lab values and no recent ADEs
A patient with intact cognition and renal function who actively participates in medication decision-making
Medication changes driven by a single specialist for a single condition without crossover effects to other systems

The AGS and the American Board of Internal Medicine (ABIM) both recognize geriatric medicine as a subspecialty precisely because this decision-boundary judgment — knowing when the system-level view becomes necessary — requires training beyond general internal medicine or family medicine. Geriatric medicine board certification, described in detail at geriatric medicine board certification, documents that a physician has met the competency threshold for this level of assessment.

For patients showing signs that an older adult should see a geriatrician, medication complexity that has outpaced the primary care visit structure is among the most consistently cited triggers for referral.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)